# Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

> **NCT04541082** · PHASE1 · RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 102 (estimated)

## Conditions studied

- Central Nervous System Neoplasms
- Glioblastoma
- Gliosarcoma, Adult
- Anaplastic Oligodendroglioma
- Anaplastic Astrocytoma
- Pilocytic Astrocytoma
- Oligodendroglioma
- Gliomatosis Cerebri
- Pleomorphic Xanthoastrocytoma
- Anaplastic Pleomorphic Xanthoastrocytoma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Ependymoma
- Ependymoma, Anaplastic
- Medulloblastoma
- Teratoid Rhabdoid Tumor
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors
- Anaplastic Meningioma
- Atypical Meningioma
- Choroid Plexus Neoplasms
- Pineal Tumor
- Diffuse Astrocytoma
- Glial Tumor

## Interventions

- **DRUG:** ONC206

## Key facts

- **NCT ID:** NCT04541082
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-26
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541082, "Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04541082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*